197 related articles for article (PubMed ID: 11775041)
1. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors.
Stahl SM
J Clin Psychiatry; 2001 Nov; 62(11):841-2. PubMed ID: 11775041
[TBL] [Abstract][Full Text] [Related]
2. Unique pharmacological profile of aripiprazole as the phasic component buster.
Hamamura T; Harada T
Psychopharmacology (Berl); 2007 Apr; 191(3):741-3. PubMed ID: 17205315
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Grunder G; Carlsson A; Wong DF
Arch Gen Psychiatry; 2003 Oct; 60(10):974-7. PubMed ID: 14557141
[TBL] [Abstract][Full Text] [Related]
4. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
5. Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.
Der-Ghazarian T; Charntikov S; Varela FA; Crawford CA; McDougall SA
J Neural Transm (Vienna); 2010 May; 117(5):573-83. PubMed ID: 20372943
[TBL] [Abstract][Full Text] [Related]
6. Aripiprazole. Abilitat, OPC 14597.
Drugs R D; 2002; 3(1):25-7. PubMed ID: 11881525
[No Abstract] [Full Text] [Related]
7. Antipsychotic dosing: still a work in progress.
Remington G
Am J Psychiatry; 2010 Jun; 167(6):623-5. PubMed ID: 20516160
[No Abstract] [Full Text] [Related]
8. Aripiprazole in an animal model of chronic alcohol consumption and dopamine D₂ receptor occupancy in rats.
Nirogi R; Kandikere V; Jayarajan P; Bhyrapuneni G; Saralaya R; Muddana N; Abraham R
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):72-9. PubMed ID: 23421566
[TBL] [Abstract][Full Text] [Related]
9. "Hit-and-run" actions at dopamine receptors, part 1: Mechanism of action of atypical antipsychotics.
Stahl SM
J Clin Psychiatry; 2001 Sep; 62(9):670-1. PubMed ID: 11681760
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Han M; Huang XF; Deng C
Int J Neuropsychopharmacol; 2009 Aug; 12(7):941-52. PubMed ID: 19203411
[TBL] [Abstract][Full Text] [Related]
11. [Antipsychotics -- do they exist?].
Makkos Z
Neuropsychopharmacol Hung; 2014 Jun; 16(2):54-5. PubMed ID: 24978047
[No Abstract] [Full Text] [Related]
12. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
13. Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.
Varela FA; Der-Ghazarian T; Lee RJ; Charntikov S; Crawford CA; McDougall SA
J Psychopharmacol; 2014 Apr; 28(4):376-86. PubMed ID: 24045880
[TBL] [Abstract][Full Text] [Related]
14. New insights into clinical response in schizophrenia: from dopamine D2 receptor occupancy to patients' quality of life.
Goff DC
Am J Psychiatry; 2008 Aug; 165(8):940-3. PubMed ID: 18676595
[No Abstract] [Full Text] [Related]
15. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum.
Inoue A; Miki S; Seto M; Kikuchi T; Morita S; Ueda H; Misu Y; Nakata Y
Eur J Pharmacol; 1997 Feb; 321(1):105-11. PubMed ID: 9083792
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic activity of aripiprazole is not 30% of dopamine, but only about 6% under ideal antipsychotic therapy.
Hamamura T; Kodama M; Harada T
J Clin Psychiatry; 2008 May; 69(5):863-4; author reply 864-5. PubMed ID: 18681765
[No Abstract] [Full Text] [Related]
18. Focus on aripiprazole.
Green B
Curr Med Res Opin; 2004; 20(2):207-13. PubMed ID: 15006016
[TBL] [Abstract][Full Text] [Related]
19. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes.
Lawler CP; Prioleau C; Lewis MM; Mak C; Jiang D; Schetz JA; Gonzalez AM; Sibley DR; Mailman RB
Neuropsychopharmacology; 1999 Jun; 20(6):612-27. PubMed ID: 10327430
[TBL] [Abstract][Full Text] [Related]
20. [Aripiprazole use in children and adolescent psychiatric patients].
Chevreuil C; Polard E; Lemonnier E; Guillemot P; Bentué-Ferrer D;
Therapie; 2011; 66(2):123-30. PubMed ID: 21635859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
